Copy Link Print Information

Fulvestrant solution

(Synonyms: ICI 182780 solution; ZD 9238 solution; ZM 182780 solution)
152 Cited Publications
Customer Review

Based on 152 publication(s) in Google Scholar

Fulvestrant solution is mainly composed of Fulvestrant (HY-13636). Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.

For research use only. We do not sell to patients.

  • CAS No.: 129453-61-8
  • Formula: C32H47F5O3S
  • Molecular Weight:606.77
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Fulvestrant solution Chemical Structure
    Fulvestrant solution Chemical Structure
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
  • Experimental Validation Results for Fulvestrant solution
CAS No.: 129453-61-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Other In-stock Forms of Fulvestrant solution

Data Download
Other Forms of Fulvestrant solution:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Fulvestrant solution

More
Customer Validation & Images
IPWBIHCCell Proliferation/Viability AssayIn Vivo Efficacy Study
  • IP
  • Cell Proliferation/Viability Assay
  • IHC
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • WB
  • WB
  • Cell Proliferation/Viability Assay
  • WB

All Estrogen Receptor/ERR Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Fulvestrant solution Chemical Structure
    Fulvestrant solution Chemical Structure
    1/16
  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Bull. 2025 Sep 29:S2095-9273(25)00984-3. [Abstract]

    Customer Validation
     MCF7 cells were incubated in stripping medium for 3 d and were pre-treated with Fulvestrant (10 µM, 0.5 h) followed by ChIP with anti-ESRRA specific antibody.

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 22;16(1):7854. [Abstract]

    Customer Validation
     The colony formation assay was used to measure LCC2 cell proliferation after treatment with Bufalin or Fulvestrant (0-200 nM).

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 22;16(1):7854. [Abstract]

    Customer Validation
     Fulvestrant (2.0 mg/kg). Representative IHC images for detecting Ki67 expression in the tumor specimens.

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2025 Dec 17;17(829):eadp5088. [Abstract]

    Customer Validation
     Combined Palbociclib- and Fulvestrant-resistant cells, M-S and T-S, and the corresponding resistant cells, MPF-R and TPF-R, were treated with different inhibitors of the PI3K/AKT/mTOR pathway including Alpelisib (HY-15244; Alp; 1 μM in M-S/MPF-R and 250 to 500 nM in T-S/TPF-R), Capivasertib (Cap; 250 to 500 nM in M-S/MPF-R and 100 nM in T-S/TPF-R), Sapanisertib (Sap; 10 nM in M-S/MPF-R and 5 nM in T-S/TPF-R), and Gedatolisib (HY-10681; Ged; 10 nM) in combination with Palbociclib (HY-50767; Palbo; 200 nM) and Fulvestrant (HY-13636; Fulv; 100 nM) (n = 3 independent biological replicates per group, performed in duplicates).

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2025 Dec 17;17(829):eadp5088. [Abstract]

    Customer Validation
     Combined Palbociclib- and Fulvestrant-resistant cells (wild type ER+ breast cancer cells), ZPF-R, and the corresponding sensitive cells, Z-S, were treated with different inhibitors of PI3K/AKT/mTOR including Alpelisib (HY-15244; 6 μM), Capivasertib (50 nM), Sapanisertib (5 nM), and Gedatolisib (HY-10681; 5 nM) in combination with Palbociclib (HY-50767; 150 nM) and Fulvestrant (HY-13636; 100 nM) (n = 3 independent biological replicates per group, performed in duplicates).

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2025 Dec 17;17(829):eadp5088. [Abstract]

    Customer Validation
     Triple combination with Gedatolisib (HY-10681), Palbociclib (HY-50767), and Fulvestrant (HY-13636) effectively inhibits growth of PIK3CA-mutant ER+ tumor xenografts resistant to combined palbociclib and fulvestrant. MPF-R cells (1 × 106) resistant to combined palbociclib and fulvestrant were injected into the mammary fat pads of NOG CIEA mice, and tumors were allowed to establish for 2 weeks to a size of ≈30 mm3. Mice were then treated with the combination of Fulvestrant (100 mg/kg, sc weekly), Palbociclib (25 mg/kg, oral gavage daily), and Capivasertib (100 mg/kg, oral gavage daily; n = 6) or Alpelisib (HY-15244; 25 mg/kg, oral gavage daily; n = 5). Tumor size was measured weekly. Average tumor growth curves measured weekly and Tumor volumes measured after excision.

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Apr;56(4):663-674. [Abstract]

    Customer Validation
     Protein expression of ER and MYC during 1 h Fulvestrant treatment (100 nM) in MCF7 cells.

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Mar 16;37(3):387-402.e7. [Abstract]

    Customer Validation
     MCF-7 cells were seeded in 10-11 M E2 to which Fulvestrant (F), Dabrafenib (D), Trametinib (T) or Selumetinib (S) were subsequently added at 10-9, 10-6, 10-7 or 10-6 M, respectively. After 6 days, proteins were measured by immunoblotting, and phosphorylation levels (as defined by the levels of the phosphorylated form over total protein) relative to the vehicle-treated cells were set to 1.

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Mar 16;37(3):387-402.e7. [Abstract]

    Customer Validation
     Top: cells were grown for 6 days in the presence of 10-11 M E2 and 10-9 M Fulvestrant, to which increasing concentration of Selumetinib was added. Cell numbers relative to the vehicle control are plotted. Bottom: the cells were treated similarly except 10-6 M Selumetinib was used, and apoptosis was measured 6 days post-treatment.

  • 1/16

    Fulvestrant solution purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2019 Apr;97(4):541-552. [Abstract]

    Customer Validation
     HK-2 cells treated with genistein (15 μM) and/or TGFβ (5 ng/ml) for 24 h are assayed with anti-acetylated and anti-total histone 3 antibodies by Western blot. In a separate assay, cell lysates treated with TGFβ and genistein in the presence or absence of Fulvestrant (Fulvest, 1 μM) under the same condition were also assayed. The quantifications are presented underneath the blots based on three independent experiments.

  • Fulvestrant solution